RHP 2.66MTRN 7.75PSMT 0ESLOY 0MSFT -5.33META -4.17HLPR.TO -0.04VDY.TO -0.65
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

24.13
-0.59 (2.39%)
as of Jun 24, 2026, 4:17:43 pm Market Open.
581 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 24, 2026, 12:00 am

This summary was created by AI, based on 29 opinions in the last 12 months.

Pfizer Inc (PFE) is facing significant challenges as it navigates a patent cliff and the subsequent impacts on revenue after its COVID-19 vaccine boom. Many analysts express concerns about the lack of earnings momentum and the uncertain prospects for new blockbuster drugs in its pipeline. Despite these challenges, PFE maintains an attractive dividend yield ranging from 6% to 7% that provides a steady income for shareholders. The company's strategy includes cost-cutting measures and acquiring smaller companies to refill its drug development pipeline. However, the stock typically trades at a low price-to-earnings ratio, indicating a lack of confidence in future growth, with multiple experts suggesting a need for patience and a potential wait for positive catalysts to drive price appreciation.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
NVO
PAST TOP PICK

Pfizer Inc(PFE)

Nov 28, 2001
(Was a top pick on Sept 26 up 16%) Still likes. A lot more upside yet.
Photo of Joe ConnollyJoe ConnollyUnlock Rating
$43.17

Stock price when the opinion was issued

$24.13

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Nov 28, 2001
Has a good pipeline for new drugs.
Photo of Mark Jackson, CFAMark Jackson, CFAUnlock Rating
$43.17

Stock price when the opinion was issued

$24.13

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Pfizer Inc(PFE)

Nov 08, 2001
Good products. Buy on weakness.
Photo of Brendan CaldwellBrendan CaldwellUnlock Rating
$42.30

Stock price when the opinion was issued

$24.13

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 30, 2001
One of the best drug companies.
Photo of Neil MurdockNeil MurdockUnlock Rating
$42.45

Stock price when the opinion was issued

$24.13

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Oct 30, 2001
(Was a top pick on April 12 up 4.6%) Good sector.
Photo of Neil MurdockNeil MurdockUnlock Rating
$42.45

Stock price when the opinion was issued

$24.13

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 25, 2001
Trades in a range. Good company.
Photo of Brendan CaldwellBrendan CaldwellUnlock Rating
$43.01

Stock price when the opinion was issued

$24.13

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 27, 2001
Stable. Trading in the mid $20's is an earning multiple based on the 15% growth expected. Has competition.
Photo of Gordon Higgins, CA, MBAGordon Higgins, CA, MBAUnlock Rating
$39.75

Stock price when the opinion was issued

$24.13

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 26, 2001
A defense stock. Ability to produce new drugs. Great patent protection. Great product line.
Photo of Joe ConnollyJoe ConnollyUnlock Rating
$38.55

Stock price when the opinion was issued

$24.13

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 24, 2001
Likes. Best product line and a good pipeline. AT a good price.
Photo of Brendan CaldwellBrendan CaldwellUnlock Rating
$36.03

Stock price when the opinion was issued

$24.13

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 24, 2001
Cheap. Great pipeline. Low risk.
Photo of Glenn Paradis, BA, CFAGlenn Paradis, BA, CFAUnlock Rating
$36.03

Stock price when the opinion was issued

$24.13

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 21, 2001
Should do well even in a recession. Good price.
Photo of Steven WipperstegSteven WipperstegUnlock Rating
$35.80

Stock price when the opinion was issued

$24.13

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 10, 2001
Prefers this and American Home over Lilly. Good product line.
Photo of Brad WillockBrad WillockUnlock Rating
$38.17

Stock price when the opinion was issued

$24.13

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Aug 30, 2001
Aging population. Nine new drugs coming out in the next 3 years. Great pipeline. 40% growth.
Photo of Joe ConnollyJoe ConnollyUnlock Rating
$38.30

Stock price when the opinion was issued

$24.13

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Aug 14, 2001
(Was a top pick on Apr 12/01 even) Still a big fan. Good sector to be in. Strong pipeline. Reports are good. Good price.
Photo of Neil MurdockNeil MurdockUnlock Rating
$41.07

Stock price when the opinion was issued

$24.13

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Aug 08, 2001
Have a tremendous pipeline for new drugs.
Photo of Rob CallanderRob CallanderUnlock Rating
$40.10

Stock price when the opinion was issued

$24.13

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
Showing 841 to 855 of 883 entries

You may also like

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

MSFT -5.33$368.61
PPL.TO -0.78$66.2
CVE.TO -1.63$34.95
TOU.TO -0.9$59.64
GOOG -3.07$343.01

Today's Top Picks

RHP 2.66$126.89
MTRN 7.75$273.09
PSMT 0$
ESLOY 0$95.66
MSFT -5.33$368.61

Popular Articles

Latest Sell Signals

ATD.TO 1.8$93.67
ITB 6.16$103.49
GLD -11.47$365.85
MU -48.27$1003.5
MU -48.27$1003.5

Most Recent Experts

Brendan Caldwell

Brendan Caldwell

Caldwell Securities

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

Paul Harris, CFA

Paul Harris, CFA

Harris Douglas Asset Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video